At one month post-launch, one in five surveyed nephrologists has started to use Veltassa in clinical practice, according to Spherix Global Insights, GmbH February 11, 2016 – Zug, Switzerland A recent survey conducted by Spherix Global Insights with 101 US…
Roughly half of surveyed pulmonologists treating patients with IPF have concerns about tolerability and side effects with currently available options, according to Spherix Global Insights, GmbH Nov 30, 2015 – Zug, Switzerland – Feedback gathered from the recently released Market…
Oct 14, 2015 – Zug, Switzerland – Feedback gathered from300 US nephrologists inthe last three releases of RealTime Dynamix: Bone and Mineral Metabolism, suggests that Auryxia is finally on the upswing. Despite strong buy-in to the benefits of Auryxia and…
Relypsa’s Patiromer FOS and ZS Pharma’s ZS-9 could revolutionize the way hyperkalemia is managed according to Spherix Global Insights, GmbH September 30, 2015 – Zug, Switzerland –In a large scale study of 548 cardiologists and nephrologists in the US and…
Acquisition expands high quality insights services to rare diseases and a focus on integrating the patient perspective into core offerings September 30, 2015 – Zug, Switzerland –In line with organizational strategy to offer unparalleled insights across professional and patient groups,…
Over 65% of neurologists believe that payers will make generic Copaxone a step edit in multiple sclerosis therapy, according to Spherix Global Insights, GmbH September 28, 2015 – Zug, Switzerland –Feedback gathered from 99 neurologists in the most recent release…